Geron (NASDAQ:GERN) Stock Falls 6% - Should You Sell?

Key Points

• Geron shares fell 6% to approximately $1.1650 in mid-day trading, with volume around 3.87 million shares—71% below the average daily volume.
• Analysts maintain a consensus “Hold” rating and a $4.00 price target, although ratings include two Buys, two Holds, and one Sell.
• Geron’s latest quarter showed a $0.02-per-share loss, missing estimates by $0.01, despite revenue of $57.48 million exceeding expectations; the company remains unprofitable while developing and commercializing Rytelo for blood-cancer treatment.

Geron Corporation (NASDAQ:GERN - Get Free Report)'s stock price fell 6% during mid-day trading on Wednesday. The stock traded as low as $1.16 and last traded at $1.1650. Approximately 3,871,784 shares traded hands during mid-day trading, a decline of 71% from the average daily volume of 13,533,929 shares. The stock had previously closed at $1.24.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Geron from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $4.00.

Geron Stock Down 6.0%

The firm's 50-day moving average price is $1.37 and its 200-day moving average price is $1.40. The company has a debt-to-equity ratio of 0.55, a current ratio of 6.91 and a quick ratio of 5.16. The company has a market cap of $748.48 million, a price-to-earnings ratio of -10.59 and a beta of 0.61.

Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.01). The company had revenue of $57.48 million for the quarter, compared to analyst estimates of $55.30 million. Geron had a negative return on equity of 24.48% and a negative net margin of 34.17%. Sell-side analysts forecast that Geron Corporation will post -0.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Hsbc Holdings PLC bought a new position in shares of Geron during the second quarter worth about $25,000. LCM Capital Management Inc acquired a new stake in Geron in the third quarter worth $25,000. GTS Securities LLC increased its holdings in shares of Geron by 71.6% in the 2nd quarter. GTS Securities LLC now owns 23,772 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 9,921 shares during the period. OneDigital Investment Advisors LLC acquired a new stake in shares of Geron in the second quarter valued at approximately $38,000. Finally, Corient Private Wealth LP raised its stake in Geron by 218.7% during the 2nd quarter. Corient Private Wealth LP now owns 34,455 shares of the biopharmaceutical company's stock valued at $44,000 after acquiring an additional 23,643 shares in the last quarter. Institutional investors and hedge funds own 73.71% of the company's stock.

About Geron

Geron Corporation NASDAQ: GERN is a biopharmaceutical company focused on developing and commercializing treatments for blood cancers and other serious hematologic disorders. Its lead product is Rytelo (imetelstat), a telomerase inhibitor designed to target malignant cells by interfering with telomere maintenance.

In 2024, the U.S. Food and Drug Administration approved Rytelo for adults with lower-risk myelodysplastic syndromes who require regular red blood cell transfusions and have not responded adequately to, or have lost response to, or are ineligible for, erythropoiesis-stimulating agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.